The heart exhibits remarkable adaptive responses to a wide array of genetic and extrinsic factors to maintain contractile function. When compensatory responses are not sustainable, cardiac dysfunction occurs, leading to cardiomyopathy. The many forms of cardiomyopathy exhibit a set of overlapping phenotypes reflecting the limited range of compensatory responses that the heart can use. These include cardiac hypertrophy, induction of genes normally expressed during development, fibrotic deposits that replace necrotic and apoptotic cardiomyocytes, and metabolic disturbances. The compensatory responses are mediated by signaling pathways that initially serve to maintain normal contractility; however, persistent activation of these pathways leads to cardiac dysfunction. Current research focuses on ways to target these specific pathways therapeutically.

Introduction
The heart relies on a complex network of cells to maintain appropriate function. Cardiomyocytes, the contracting cells in the heart, exist in a three-dimensional network of endothelial cells, vascular smooth muscle, and an abundance of fibroblasts as well as transient populations of immune cells. Gap junctions electrochemically coordinate the contraction of individual cardiomyocytes, and their connection to the extracellular matrix (ECM) transduces force and coordinates the overall contraction of the heart. Intracellularly, repeating units of actin and myosin form the backbone of sarcomere structure, the basic functional unit of the cardiomyocyte (Fig. 1). The sarcomere itself consists of ~20 proteins; however, more than 20 other proteins form connections between the myocytes and the ECM and regulate muscle contraction (Fig. 1 B). Given the complexity of the coordinated efforts of the many proteins that exist in multimeric complexes, dysfunction occurs when these interactions are disrupted.

Although the heart may functionally tolerate a variety of pathological insults, adaptive responses that aim to maintain function eventually fail, resulting in a wide range of functional deficits or cardiomyopathy. Although a multitude of intrinsic and extrinsic stimuli promote cardiomyopathies, the best described causes are the >900 mutations in genes expressed in the cardiomyocyte (Fig. 1 B; Wang et al., 2010). Mutations in most of these genes cause a diverse range of cardiomyopathies, many with overlapping clinical phenotypes. Mutations in sarcomeric genes are usually inherited in an autosomal-dominant manner and are missense mutations that are incorporated into sarcomers (Seidman and Seidman, 2001). Thus far >400 mutations in 13 sarcomeric proteins including β-myosin heavy chain (β-MyHC), α-cardiac actin, tropomyosin, and troponin have been associated with cardiomyopathy (www.cardiogenomics.med.harvard.edu). Table I summarizes these mutated proteins.

There are several examples in which mutations in the same gene can cause different disease phenotypes (indicated in bold in Table I), suggesting that the position of the mutation within the gene influences the cardiac phenotype. Clinical phenotypes are also likely to be modified by sex hormones, diet, and polymorphisms in many genes including those involved in angiotensin signaling, thus complicating attempts to make predictive correlations between specific mutations with disease prognosis (Maron et al., 1995; Deinum et al., 2001; Stauffer et al., 2006). In fact, a modifier gene was identified in one strain of mice that blocked the pathology induced by a mutated β-MyHC (R403Q) in another strain of mice (Semsarian et al., 2001). Characterization and mechanistic study of cardiomyopathies are therefore challenging owing to the complex protein structures, the multitude of disease-causing mutations, and modulators of pathology.

A wide range of inherited and acquired cardiomyopathies has been described by the World Health Organization: hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy as well as a large group of unclassified cardiomyopathies. Acquired cardiomyopathies induced by stress, diabetes, some chemotherapeutic agents, pregnancy, and alcohol intake, for example, represent a diverse class of cardiac disease (Bybee et al., 2004; Ro and Frishman, 2006; Dolci et al., 2008; Dobrin and Lebeche, 2010; Iacovoni et al., 2010). In this review,
It is not yet clear whether clinical predictions can be made based solely on which functional domains carry mutations. Cardiac dysfunction in HCM is attributable to initial increases in heart mass and asymmetric interventricular septal thickening (Fig. 2, A and B; Maron et al., 1995; Marian, 2000; Wang et al., 2010). Histological hallmarks include an increase in cardiomyocyte size, disorganized arrangement of myocytes (myofibrillar disarray), and both perivascular and interstitial fibrosis, a common phenotype in many cardiomyopathies. Persistent cardiac architectural changes in HCM can result in thinning of the ventricular walls, dilation of the ventricular chamber, and decreases in cardiac output that can lead to heart failure.

Dilated cardiomyopathy (DCM). DCM occurs in 1 in 2,500 individuals in the United States and is considered the most prevalent form of cardiomyopathy because it is a common clinical outcome of many prolonged cardiac insults (Cregler, 1989; Vikstrom et al., 1996). Enlargement of the ventricular chamber and thinning of the ventricular walls are the predominant phenotypes in this disease (Fig. 2 C). Loss of heart mass is highly correlated with heart failure and mortality; indeed, 50%...
| Disease                          | Mutated gene                                      | Pathology                                                                 |
|---------------------------------|---------------------------------------------------|---------------------------------------------------------------------------|
| Hypertrophic cardiomyopathy     | Myosin binding protein C                           | Increased heart mass                                                      |
|                                 | β-Myosin heavy chain                               | Left ventricular wall thickening                                          |
|                                 | α-Myosin heavy chain                               | Increased cardiomyocyte size                                              |
|                                 | α-Tropomyosin                                      | Myofibrillar disarray                                                    |
|                                 | Troponin T                                        | Decreased volume of left ventricular chamber                              |
|                                 | α-Cardiac actin                                    | Interstitial fibrosis                                                    |
|                                 | Troponin I                                        | Enlarged nuclei                                                          |
|                                 | Titin                                             | Ventricular wall stiffness                                               |
|                                 | Myosin light chains                               | Inflammation                                                             |
|                                 | Tropinin                                          |                                                                           |
|                                 | Vinculin                                          |                                                                           |
|                                 | Muscle LIM protein                                |                                                                           |
|                                 | Telophotonin                                      |                                                                           |
|                                 |                                                   |                                                                           |
| Dilated cardiomyopathy          | β-Myosin heavy chain                              | Ventricular wall thinning                                                |
|                                 | Desmin                                            | Ventricular chamber enlargement                                          |
|                                 | N-cadherin                                        | Cardiomyocyte apoptosis                                                  |
|                                 | α-Cardiac actin                                    | Interstitial fibrosis                                                    |
|                                 | Skeletal muscle myopathies                        | Enlarged nuclei                                                          |
|                                 | α-Tropomyosin                                      | Ventricular wall stiffness                                               |
|                                 | Muscle LIM protein δ-sarcoglycan                   |                                                                            |
|                                 | Lamin A/C                                         |                                                                            |
|                                 | TAZ (G4.5)                                        |                                                                            |
|                                 | Titin                                             |                                                                            |
|                                 | Phospholamban                                     |                                                                            |
|                                 | Vinculin                                          |                                                                            |
|                                 | Troponin I                                        |                                                                            |
|                                 | Troponin T2                                       |                                                                            |
|                                 | SCN5A                                             |                                                                            |
|                                 | Presenilin 1 & 2                                  |                                                                            |
|                                 | Troponin C                                        |                                                                            |
|                                 | α-Cardiac actinin                                  |                                                                            |
|                                 | Plakoglobin                                        |                                                                            |
|                                 |                                                   |                                                                           |
| Restrictive cardiomyopathy      | Troponin I                                        | Ventricular wall stiffness                                               |
|                                 | Desmin                                            | Apoptosis                                                                 |
|                                 | α-Cardiac actin                                    | Fibrosis                                                                  |
|                                 | Skeletal muscle myopathies                        | Myofibrillar disarray                                                    |
|                                 | Troponin T                                        |                                                                            |
|                                 | β-Myosin heavy chain                              |                                                                            |
|                                 | TAZ (G4.5)                                        |                                                                            |
|                                 | α-Dystrobrevin                                     |                                                                            |
|                                 | FKBP12                                             |                                                                            |
|                                 | β-Myosin heavy chain                              | Trabeculated ventricular walls                                           |
|                                 | α-Cardiac actin                                    | Noncompaction of ventricular endocardium                                 |
|                                 | Cardiac troponin                                  | Necrotic myocytes                                                        |
|                                 |                                                   |                                                                            |
| Left ventricular noncompaction   | TAZ (G4.5)                                        |                                                                            |
|                                 | α-Dystrobrevin                                     |                                                                            |
|                                 | FKBP12                                             |                                                                            |
|                                 | β-Myosin heavy chain                              |                                                                            |
|                                 | α-Cardiac actin                                    |                                                                            |
|                                 | Cardiac troponin                                  |                                                                            |
|                                 | Plakophilin-2                                      | Right ventricular dilation                                               |
|                                 | Junctional plakoglobin                            | Right ventricular fibrosis                                               |
|                                 | Desmocollin-2                                     | Fibrofatty infiltration                                                  |
|                                 | Desmoglein-2                                      | Apoptosis                                                                |
|                                 | Desmoplakin                                       |                                                                            |
|                                 |                                                   |                                                                            |
| Arrhythmogenic right ventricular cardiomyopathy | Plakophilin-2                                      |                                                                            |
|                                 | Junctional plakoglobin                            |                                                                            |
|                                 | Desmocollin-2                                     |                                                                            |
|                                 | Desmoglein-2                                      |                                                                            |
|                                 | Desmoplakin                                       |                                                                            |
|                                 |                                                   |                                                                            |
| Muscular dystrophy–associated cardiomyopathy | Dystrophin                                         | Left ventricular hypertrophy or dilation                                 |
|                                 | Sarcoglycan                                       | Fibrosis                                                                 |
|                                 | Dystroglycan                                       |                                                                            |
|                                 | Dystrobrevin                                      |                                                                            |

Bold: mutations that are common to multiple forms of cardiomyopathy.
of those diagnosed with DCM die within five years of becoming symptomatic (Michels et al., 1992; Grogan et al., 1995).

Although DCM can occur secondary to systemic pathology, approximately one half of cases are not associated with a systemic cause (idiopathic DCM). Among these cases, about one third of patients have a family history of DCM (familial DCM) that is transmitted autosomal recessively (and dominant), through maternal mitochondrial DNA, or as an X-linked mutation (Berko and Swift, 1987; Keeling et al., 1995; Mestroni et al., 1999). In contrast to HCM, which is almost exclusively associated with mutations in sarcomeric proteins, familial DCM is primarily associated with mutations in cytoskeletal proteins (Table I). These and other proteins that connect the sarcomere to the ECM form the mechanotransduction apparatus that allows cardiomyocytes to sense and respond to changes in contractility. Disruption of components of this apparatus therefore prevents the heart from productively responding to both extrinsic and intrinsic stressors.

Restrictive cardiomyopathy (RCM). RCM is the least common but most lethal form of cardiomyopathy (Davis et al., 2007). Causes of RCM are extremely variable and include induced and genetic initiators as well as idiopathic etiologies. Idiopathic RCM occurs in the absence of other pathology, although it can be associated with skeletal muscle myopathies (Katrakis et al., 1991). Injury to the heart caused by radiation, scarring after heart surgery, infection, or diseases such as amyloidosis can also cause RCM. Recently, mutations in the sarcomeric protein troponin I, which participates in the regulation of calcium-mediated actin–myosin interactions and contractility, were associated with a familial form of the disease, and it is now recognized as the primary disease-causing mutation in familial RCM (Mogensen et al., 2003). Mutations in other sarcomeric proteins such as cardiac desmin, α-cardiac actin, and β-MyHC as well as mutations that have been implicated in HCM have been described in RCM patients (Karam et al., 2008; Parvatiyar et al., 2010).

Unlike in HCM, alterations in tissue flexibility occur in RCM in the absence of changes in ventricular myofibrillar arrangement and gross abnormalities (Huang and Du, 2004). RCM is, therefore, characterized by increased stiffness of the myocardium that causes increased pressure in one or both ventricles. Ventricular relaxation is impaired, similar to the phenotype observed in HCM, and the atria then enlarge in response to the increased pressure in some patients (Parvatiyar et al., 2010). The restrictive phenotype is common to RCM and some cases of HCM, emphasizing the need for more precise diagnostic criteria.

Figure 2. Gross pathology associated with cardiomyopathies. Illustrations depicting (A) a healthy heart with normal wall thicknesses and chamber volumes and (B) hypertrophic cardiomyopathy. Asymmetric hypertrophy of the interventricular septum as well as the left ventricular posterior wall and apex is present. (C) Dilated cardiomyopathy. Thinning of the ventricular walls enlarges the interior dimensions of the ventricular chamber. The left and right atria are also enlarged due to impaired ventricular relaxation. (D) Left ventricular noncompaction. Trabeculated ventricular walls create a spongy appearance, prominent in the left ventricular wall. Ao, aorta; LA, left atrium; LV, left ventricle; RV, right ventricle.

Arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC occurs in ~1 in 5,000 individuals and primarily affects adults (Basso et al., 2009). However, ARVC is also an important cause of death among young people, accounting for ~20% of deaths occurring in individuals under 30 years old (Shen et al., 1995). ARVC is inherited in an autosomal-dominant or recessive pattern in 50% of cases often with incomplete penetrance, so unknown genetic or environmental modifiers are predicted (Basso et al., 2009).

Mutations in proteins that comprise the cardiac desmosome, a junctional complex that mechanically couples neighboring cardiomyocytes to coordinate contractile activity, account for most inherited cases of ARVC (Yang et al., 2006). Disruptions in desmosome stability cause structural and functional alterations and are associated with cardiomyocyte apoptosis (Yamaji et al., 2005). Adipose and fibrotic tissue that replace cardiomyocytes are a hallmark of ARVC, primarily in the right ventricle; however, left ventricular involvement is common in later stages of the disease (Corrado et al., 1997). The right ventricle enlarges as myocyte loss progresses, causing a reduction in blood volume pumped from the heart and arrhythmias.

Left ventricular noncompaction cardiomyopathy (LVNC). LVNC, a recently delineated form of cardiomyopathy, is defined anatomically by deep trabeculations that create a spongiform appearance of the ventricular walls (Fig. 2D; Chin et al., 1990). Clinically, patients present with depressed systolic and diastolic dysfunction, left and right ventricular hypertrophy, arrhythmias, and, in some cases, conduction block. Familial forms with autosomal-dominant or X-linked transmission account for up to 50% of all LVNC cases (Chin et al., 1990; Sasse-Klaassen et al., 2003). The mechanisms responsible for pathology are poorly defined, but indirect evidence suggests that malformation of the myocardium contributes to functional abnormalities in the adult (Yousef et al., 2009). During development, the loose network of fibers that form the myocardium becomes compacted between the fifth and eighth prenatal weeks. In patients with LVNC, a normal pattern of compaction occurs in the outer band of the myocardium, but an abnormal noncompacted region within the inner (endocardial) layer localized mainly in the apical and midventricular regions of the heart is also observed (Fig. 2D; Chin et al., 1990; Ritter et al., 1997; Freedom et al., 2005). Similarities among LVNC, HCM, and DCM, likely caused by mutations in the same gene (β-MyHC, for example), motivate differential diagnosis criteria aimed at better defining this syndrome (Weiford et al., 2004; Kaneda et al., 2008).
Cardiomyopathies associated with muscular dystrophies. Muscular dystrophies, caused by autosomal-recessive mutations in proteins that anchor the sarcomere to the ECM, are a heterogeneous group of skeletal muscle disorders. Incidence of cardiac involvement among patients with muscular dystrophies varies and is dependent upon the disease-causing mutations. Although Duchenne and Becker muscular dystrophies are X-linked, up to 18% of female carriers that do not exhibit skeletal muscle disease exhibit heart failure, illustrating that even subtle disruption of the interactions between the sarcomere and ECM can impart cardiac dysfunction (Hoogerwaard et al., 1999).

Identification of disease-causing mutations in the heart has contributed to the delineation of many phenotypically similar cardiomyopathies. However, much work remains in elucidating the specific cellular mechanisms of disease. In the past decade, resources available to study cardiomyopathies at the cellular level have evolved to allow the study of mechanisms of pathogenesis using a variety of experimental approaches including in vitro biochemistry, cell biology, and animal models (Flavigny et al., 1999; Haq et al., 2000; Maas and Buvoli, 2007). These studies have revealed the roles of a variety of cell types in the development of cardiomyopathy. In addition to cardiomyocyte-mediated effects, nonmyocytes induce functional changes in cardiomyocytes and in the structural properties of the ECM. Deposition of collagen by fibroblasts, for example, creates fibrotic scars that stiffen the heart tissue and impede normal cardiomyocyte contractility. In the sections that follow, we present an overview of the cellular pathology mediated by cardiac cells with an emphasis on the cardiomyocyte, whose responses to intrinsic and extrinsic insults most profoundly affect cardiac function.

Altered cardiomyocyte cell biology in cardiomyopathy

Different classifications of cardiomyopathy exhibit a subset of overlapping symptoms, emphasizing the limited range of cellular responses in the cardiomyocyte (Table I). Alterations in gene expression patterns, changes in cellular morphology, and metabolic shifts in cardiomyocytes initially improve or maintain function in the early stages of many forms of cardiomyopathy. An exception to this is DCM, which does not appear to progress through this initial series of compensatory responses. Patients with DCM exhibit a dilated phenotype that decompensates rapidly when patients become symptomatic, similar to end-stage heart failure HCM.

Cardiomyocyte hypertrophy. In response to altered contractility or physiological stress, ventricular cardiomyocytes increase in size to keep pace with increased functional demand, thus increasing the thickness of the walls but reducing interior dimensions of the ventricular chambers. Regardless of the initial stimulus, cardiac hypertrophy is thought to be compensatory as it normalizes increased stress in the ventricular wall and augments the contractile capacity of the heart. The development of hypertrophy therefore implies an anatomical adaptation that does not explicitly signify a disease state.

Cardiac hypertrophy is attributable to structural alterations within individual cardiomyocytes. The addition of sarcomeres in parallel is an adaptive response to increase force production in stressed cells. Increased myocyte width (concentric hypertrophy; Fig. 3, A and B) correlates with compensatory ventricular hypertrophy, a hallmark of HCM. In HCM, however, concentric hypertrophy causes a distortion of the cardiomyocyte alignment, which may affect contractility in the heart (Seidman and Seidman, 2001). There remains no clear consensus on whether cardiomyocyte hypertrophy is truly compensatory or merely a component in the pathway to heart failure. However, when hypertrophic growth in a myosin model of HCM was blocked by constitutive activation of glycogen synthase kinase 3β (GSK3β), all male animals died, suggesting that the initial phases of hypertrophy are indeed compensatory (Luckey et al., 2009). Persistent hypertrophy with disease is positively associated with the development of heart failure. After an initial phase of compensatory hypertrophy, addition of sarcomeres to ventricular cardiomyocytes increases length-to-width ratios, which leads to decreased force production. Increased myocyte length produced by end-to-end addition of sarcomeres (eccentric hypertrophy; Fig. 3, C and D) is associated with ventricular dilation in DCM and with advanced HCM.

Fetal gene program. In cardiomyopathy, induction of genes normally expressed during embryogenesis occurs including natriuretic factors, β-MyHC, and α-skeletal actin (Kuwahara et al., 2003). Natriuretic proteins secreted by cells in the atria and ventricles, atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP), respectively, induce diuresis and vasodilation, which are capable of reducing blood volume and pressure in response to increased wall stress. These factors are up-regulated in response to transient increases in blood pressure. However, in cardiomyopathy, transcription and secretion are chronic.

ANF expression is increased in atrial myocytes when hearts exhibit diastolic dysfunction, which increases tension on the walls of the atria, and is released by ventricular myocytes when there is increased pressure on the ventricular walls in cardiomyopathy (Rodeheffer et al., 1986; Edwards et al., 1988). Ventricular hypertrophy causes excessive stress in the ventricular wall during contraction, which also serves as a stimulus for release of BNP (Kinnunen et al., 1993). Induced expression of these genes, therefore, implies a cardioprotective mechanism that indirectly attempts to normalize pathological changes that affect the heart. Some evidence suggests that these genes may be anti-hypertrophic to prevent overgrowth of the organ in response to stress (Silberbach et al., 1999).

Myosin isoform shift. In the face of a wide variety of pathological insults, up-regulation of the β-MyHC isoform occurs. Myosin exists as two heavy chains and two pairs of light chains. Cardiac muscle contains two isoforms of MyHC, α-MyHC and β-MyHC, which are expressed in species-specific proportions in the heart. β-MyHC accounts for more than 90% of the MyHC in the adult human ventricle. The proportion of these isoforms in the heart is tightly regulated, such that up-regulation of β-MyHC expression with a concomitant decrease in α-MyHC in the hearts of humans and rodents is a sensitive
disruption of excitation–contraction coupling between cardiomyocytes and increased stiffness of the myocardium, and leads to decreased contractility in the heart (Menon et al., 2009). Fibrosis is primarily produced by resident fibroblasts in the heart; however, there is evidence for collagen production by cardiomyocytes (Schram et al., 2010). Recent studies support a link between sarcomere mutations and gene expression changes in nonmyocytes that promotes production of fibrosis. Increased transcription and release of TGF-β in the hearts of mice expressing HCM-causing mutations in α-MyHC (R403Q, R719W) activate nonmyocytes and promote increased focal and interstitial fibrosis (Teekakirikul et al., 2010). Interference with the development of excessive fibrosis in the hearts of patients with cardiomyopathy could represent a promising therapy to reduce the functional deficits that result from disease-causing mutations in cardiomyocytes.

Alteration in metabolic substrate utilization. In the healthy heart, phosphocreatine is the main reserve source of ATP during acute stress. As pathogenesis progresses in cardiomyopathy, the demand for ATP increases, and the levels of phosphocreatine are progressively depleted (Ingwall and Weiss, 2004; Smith et al., 2006). This reduction in energy-rich resources forces the heart to favor alternative energy substrates.

Figure 3. Isolated cardiomyocytes exhibiting hypertrophy and heart failure. (A) Untreated adult ventricular cardiomyocyte demonstrating normal brick-like morphology. (B) An adult ventricular cardiomyocyte treated with endothelin-1 precursor protein exhibiting significant concentric hypertrophy. The cardiomyocyte is decreased in length and increased in width, consistent with the phenotype observed in human cardiomyocytes with concentric hypertrophy. A and B are reproduced from Gupta et al. (2005) with permission from Elsevier. (C) Cardiomyocyte isolated from a healthy human heart. (D) Cardiomyocyte isolated from the heart of a patient in heart failure. Increased length and decreased width are characteristic of eccentric hypertrophy. C and D are reproduced from Ohter et al. (2009) with permission from Brian O’Rourke.

marker of early cardiomyopathy (Lowes et al., 1997; Miyata et al., 2000). This response may be adaptive, as β-MyHC exhibits lower ATPase activity resulting in improved ATP use, and may be a requirement in the presence of mutations that reduce efficiency of contractility. However, features of β-MyHC, which exhibits slower filament sliding velocity, may contribute to pathology (Schwartz et al., 1981).

Contractility of the heart is inversely proportional to the amount of expression of β-MyHC (Palmiter et al., 1999; Herron and McDonald, 2002). Titration of β-MyHC expression in adult ventricular cardiomyocytes results in a dose-dependent reduction in sarcomere shortening and velocity, independent of Ca\(^{2+}\) handling (Herron et al., 2007). The shift toward β-MyHC in the pathological heart may contribute to the decreased myocyte shortening and prolonged relaxation of cardiomyocytes observed during the transition from compensatory hypertrophy to heart failure (Nagata et al., 1998).

Fibrosis. The development of interstitial and perivascular fibrosis is a hallmark of pathology in the heart. Focal fibrosis, composed primarily of collagen types I and III, occurs in the early stages of cardiomyopathy, but over time fibrosis increases and directly compromises the function of cardiomyocytes. The presence of collagen-rich regions in the myocardium causes disruption of excitation–contraction coupling between cardiomyocytes and increased stiffness of the myocardium, and leads to decreased contractility in the heart (Menon et al., 2009). Fibrosis is primarily produced by resident fibroblasts in the heart; however, there is evidence for collagen production by cardiomyocytes (Schram et al., 2010).

Recent studies support a link between sarcomere mutations and gene expression changes in nonmyocytes that promotes production of fibrosis. Increased transcription and release of TGF-β in the hearts of mice expressing HCM-causing mutations in α-MyHC (R403Q, R719W) activate nonmyocytes and promote increased focal and interstitial fibrosis (Teekakirikul et al., 2010). Interference with the development of excessive fibrosis in the hearts of patients with cardiomyopathy could represent a promising therapy to reduce the functional deficits that result from disease-causing mutations in cardiomyocytes.
during prolonged stress mediated by exogenous cardiotoxic stimuli or contractile dysfunction caused by mutated sarcomeric proteins. During the initial compensatory stages of cardiomyopathy, substrate utilization favors free fatty acids, which yield about three times more ATP than glucose but require more oxygen to metabolize, making it a more lucrative but less efficient means to produce energy (Ashrafian and Frenneaux, 2007; Neubauer, 2007).

In the failing heart, as in DCM and end-stage HCM, energy substrate utilization in the heart shifts from fatty acid oxidation to glucose utilization, a less efficient means of producing energy (Stanley et al., 1997; Kalsi et al., 1999; Dávila-Román et al., 2002). A proposed mechanism for this transition from compensatory to decompensatory cardiac hypertrophy is excessive cardiac growth without adequate coronary angiogenesis. A mildly hypoxic state up-regulates genes that facilitate utilization of glucose instead of fatty acids (Huang et al., 2004). This is supported by studies in the developing heart in which exposure to the oxygen-rich postnatal environment at birth correlates with a dramatic shift in metabolic enzyme isoforms to use fatty acids as an energy substrate (Lopashuk et al., 1991). Indeed, hypertrophy induced by volume overload in newborns delays this shift (Kantor et al., 1999). Expression and activity of enzymes that mediate fatty acid use, such as medium-chain acyl-CoA dehydrogenase and peroxisome proliferator-activated receptor-α, are down-regulated in the failing adult heart to resemble the fetal heart (Sack et al., 1996). Therefore, the heart progresses through several stages of metabolic changes as it enters heart failure: the increased use of fatty acids during compensation and a shift to glucose utilization as the heart decompensates.

**Sensing and responding to cellular stress**

The cellular responses observed in cardiomyopathies arise from the detection of functional changes mediated primarily by ECM–sarcomere connections and collectively aim to maintain sufficient contractile force and prevent progression to heart failure. Signaling pathways initiated by mechanotransduction in the cardiomyocyte initially serve to reduce blood volume, add sarcomeres to increase contractile capacity, and shift metabolic processes to those that favor the utilization of substrates that yield more energy (lipids).

**Mechanotransduction and signaling in the cardiomyocyte.** The responses of cardiomyocytes to systemic stress or genetic abnormalities are modulated by mechanosensitive mechanisms within the cardiomyocyte (Molkentin and Dorn, 2001; Seidman and Seidman, 2001; Frey and Olson, 2003). A complex network of proteins that connects the sarcomere to the ECM forms the basis of the mechanotransduction apparatus. For example, components of the costamere complex, which form the connection between the sarcomere and the ECM via integrins, initiate intracellular signaling and subsequently alter contractile properties and transcriptional regulation in response to membrane distortion. Mechanosensitive ion channels are also implicated in signal initiation in response to systemic stress (Le Guennec et al., 1990; Zhang et al., 2000; de Jonge et al., 2002). These channels are likely responsible for acute changes that might initiate other longer-term responses in the heart but are nonetheless important to consider when examining possible transducers of systemic and tissue alterations to the cardiomyocyte.

Changes in wall stress induce signaling pathways that are associated with the development of cardiac pathology. The many intracellular signaling pathways that mediate responses to increased demand on the heart have been extensively reviewed elsewhere (Force et al., 1999; Molkentin and Dorn, 2001; Heineke and Molkentin, 2006). Here, we focus on pathways that are intimately involved in pathogenesis (Fig. 4). Although their effects in compensatory responses early in pathology initially increase function by promoting growth and contractility, persistent responses eventually compromise function.

**Akt signaling.** Akt, the major effector of phosphoinositide 3-kinase (PI3K) signaling, mediates many processes important to cardiac adaptation including protein synthesis, inhibition of apoptosis, and metabolism. Despite clear beneficial effects of acute Akt activation, chronic activation of the PI3K/Akt pathway causes cardiomyopathy. The divergent effects of activated Akt are dependent on the length of time Akt is activated and the initiator of the pathway. Mice expressing constitutively activated (myristoylated) Akt have hearts and cardiac myocytes that are approximately twofold larger than littermate controls and are protected from ischemia reperfusion injury. However, other founder mice expressing the transgene die with cardiac enlargement and presumed heart failure (Matsui et al., 2002). Also, a conditional mutant with activated Akt1 exhibits reversible hypertrophy with two weeks of transgene expression but irreversible hypertrophy with fibrosis and reduced angiogenesis when expressed for six weeks (Shiojima et al., 2005). Therefore, activation of Akt signaling increases cell size and contractile efficiency in the face of acute intensification of functional demand; however, the temporal activation of this pathway determines whether the adaptive effects are maintained productively (Matsui et al., 2002; O’Neill and Abel, 2005).

Downstream of Akt is the kinase GSK-3β, which negatively regulates cardiomyocyte size. GSK-3β is largely unphosphorylated and constitutively active in the healthy heart; phosphorylation of GSK-3β by Akt inactivates it. Overexpression of activated GSK-3β causes reduced heart size and decreased hypertrophy in response to pathological stimuli (Haq et al., 2000; Michal et al., 2004). In genetic models of HCM with mutations in sarcomeric proteins, GSK-3β is inactivated, consistent with hypertrophy in these models and demonstrating downstream alterations in the Akt signaling cascade (Stauffer et al., 2006; Luckey et al., 2009).

**G protein signaling.** Pathological stimuli that induce increased pressure or mechanical stretch in the heart promote release of several paracrine and autocrine factors including adrenergic factors, angiotensin II, and endothelin (ET1), which each activate G protein–coupled receptor (GPCR) signaling. G protein subunits serve as effectors for downstream signaling cascades and modulate cardiac adaptation, namely those processes intended to increase force production like cardiomyocyte hypertrophy. Mechanical stretch of adult ventricular cardiomyocytes and administration of GoS activating agents (norepinephrine,
(AngII) in neonatal rat ventricular myocytes specifically induce hypertrophy (Sadoshima and Izumo, 1993; Kojima et al., 1994). Each of the agents that activate Goq in neonatal rat ventricular myocytes also induces activation of phospholipase C and hypertrophy (Simpson et al., 1982; Knowlton et al., 1993; Adams et al., 1996; Sakata et al., 1998). In agreement with these data, Goq attenuation decreases hypertrophy, cardiac remodeling, and functional deficits in response to pressure overload in mice (Esposito et al., 2001). Transgenic mice overexpressing Goq exhibit cardiac growth similar to that induced by pressure overload, independent of this stimulus (D’Angelo et al., 1997; Sakata et al., 1998). The hearts of these mice also exhibit some qualities of pathological hypertrophy including left ventricular dysfunction and induction of the fetal gene program indicative of cardiomyopathy (D’Angelo et al., 1997; Sakata et al., 1998).

Ca²⁺ regulation and calcineurin signaling. Ca²⁺ concentrations inside the cardiomyocyte are critically important to actin–myosin interactions. Ca²⁺ is sequestered within the sarcoplasmic reticulum and the sarcosome itself, which serves as an intracellular reserve that is released in response to electrical stimulation of the cardiomyocyte. After contraction, sarco/endoplasmic reticulum Ca²⁺-ATPase sequesters the Ca²⁺ back into the sarcoplasmic reticulum to restore Ca²⁺ balance. There is a clear correlation between force production and perturbation of Ca²⁺ regulation, alterations of which might directly induce pathological, anatomical, and functional alterations that lead to heart failure via activation of GPCRs (Minamisawa et al., 1999).

Ca²⁺ in the cytosol can be increased to modulate sarcosome contractility by signaling through Goq recruitment and activation of PLCβ. Ca²⁺ released from the sarcoplasmic reticulum activates calmodulin, which phosphorylates calcineurin, a serine/threonine phosphatase. Upon activation, calcineurin interacts with and dephosphorylates nuclear factor of activated T cells (NFAT), which then translocates into the nucleus. Calcineurin activation exacerbates hypertrophic signals and expedites the transition to a compensatory state. Indeed, cardiac-specific overexpression of calcineurin or NFAT leads to significant cardiac hypertrophy that progresses rapidly to heart failure (Molkentin et al., 1998). Administration of antagonists of calcineurin attenuates the hypertrophic response of neonatal rat ventricular myocytes to stimuli such as phenylephrine (PE) and angiotensin II (Taigen et al., 2000).

Apoptotic pathways. Apoptosis has recently been shown to play a major role in cardiac disease (Gill et al., 2002). Adult cardiomyocytes are terminally differentiated, so cell loss is detrimental to cardiac function. Additionally, when cardiomyocytes are lost, deposition of collagen occurs. Ultimately, this decreases heart compliance, increases cardiomyocyte wall stress, and impairs ventricular relaxation. Apoptosis has been demonstrated in HCM and DCM as evidenced by activated apoptotic pathway components and caspase activity (Narula et al., 1996; Olivetti et al., 1997; Akyürek et al., 2001). Many of the signaling pathways activated with increased cardiomyocyte stretch are implicated in regulation of apoptosis, including Akt and adrenergic stimulation. Several groups have demonstrated that hyperactivation of β-adrenergic signaling pathways and cytochrome c release from mitochondria are associated with increased apoptosis and fibrosis (Communal et al., 1998; Geng et al., 1999; Iwai-Kanai et al., 1999; Narula et al., 1999). Additionally, evidence for increased signaling through Fas receptors by up-regulation of TNF is common in heart failure, and the degradation of inhibitors of Fas receptor signaling such as cFlip is another mechanism by which apoptosis may occur (Krown et al., 1996; Torre-Amione et al., 1996). Studies from human heart biopsies reveal that greater cell loss is observed in the early stages of cardiomyopathy, suggesting that anti-apoptotic pathways are up-regulated after...
cell loss has been initiated (Akyürek et al., 2001). It follows that tight regulation of apoptosis is required for proper cardiac development and that disruption of these pathways can have irreversible consequences in the heart.

**Summary**

Advances in molecular techniques have vastly improved the understanding of mechanisms responsible for cardiac dysfunction in cardiomyopathies. It is clear that mutant proteins in cardiomyocytes can perturb cardiac function whether they occur in the contractile apparatus or in the mechanosensitive complexes. Alterations in cardiomyocyte function initiate cascades of cellular responses that attempt to compensate for these insults by normalizing functional parameters in the cells. However, persistent responses at the cellular level lead to organ-wide alterations that are highly correlated with sudden cardiac death and heart failure. Much remains to be learned about precise mechanisms that mediate the transition between compensatory responses in the heart and the development of heart failure.

Despite these challenges, basic studies of the processes that mediate cellular responses to cardiac stress have allowed the development of therapeutics for some cardiomyopathies that include drugs that decrease blood pressure and heart rate (angiotensin II receptor antagonists, Ca2+ channel blockers) to reduce the strain on the ventricular walls. Implantable devices that regulate the synchronization of contraction also reduce the progression of cardiomyopathies (Rose et al., 2001). Although there exist no treatments to directly address the causes of inherited cardiomyopathies, cell transplantation, gene therapy, small interfering RNAs, and microRNAs remain on the horizon of innovative treatments that address the causes rather than reduction of symptoms of cardiomyopathies. Utilization of animal and cellular models to further probe the mechanisms of cardiomyopathy and demonstrate efficacy of drugs that specifically target disease-causing pathways hold promise that further reduction in the mortality associated with cardiomyopathies can be achieved.

We gratefully acknowledge Dr. Massimo Buvoli for useful discussion related to the content of this manuscript and Dr. Kristen Barthel, Dr. Matthew Bell, and Christopher Haines for critical review. We also thank Dr. Brian O’Rourke for providing images used in Fig. 3, C and D.

This work was supported by National Institutes of Health grant HL-50560 (J.A. Leinwand) and National Institutes of Health training grant T32 HL-07822 (P.A. Harvey).

Submitted: 19 January 2011
Accepted: 23 June 2011

**References**

Adams, J.W., D.S. Migita, M.K. Yu, R. Young, M.S. Hellickson, F.E. Castro-Vargas, J.D. Domingo, P.H. Lee, J.S. Bui, and S.A. Henderson. 1996. Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. *J. Biol. Chem.* 271:1179–1186. doi:10.1074/jbc.271.2.1179

Akyürek, O., N. Akyürek, T. Sayin, I. Dinçer, B. Berkalp, G. Akyol, M. Ozenci, and M. Swift. 1987. X-linked dilated cardiomyopathy. *N. Engl. J. Med.* 316:1186–1191. doi:10.1056/NEJM198705073161904

Buvoli, M., M. Hamady, L.A. Leinwand, and R. Knight. 2008. Bioinformatics assessment of beta-mysin mutations reveals myosin’s high sensitivity to mutations. *Trends Cardiovasc. Med.* 18:141–149. doi:10.1016/j.tplm.2008.04.001

Bybee, K.A., T. Kara, A. Prasad, A. Lerman, G.W. Barsness, R.S. Wright, and C.S. Rihal. 2004. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. *Ann. Intern. Med.* 141:858–865.

Chin, T.K., J.K. Perloff, R.G. Williams, K. Jue, and R. Mohrmann. 1990. Isolated noncompaction of left ventricular myocardium. A study of eight cases. *Circulation.* 82:507–513. doi:10.1161/01.CIR.82.2.507

Communal, C., K. Singh, D.R. Pimentel, and W.S. Colucci. 1998. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. *Circulation.* 98:1329–1334.

Corrado, D., C. Basso, G. Thieme, W.J. McKenna, M.J. Davies, F. Fontaliran, A. Nava, F. Silvestri, C. Blomstrom-Lundqvist, E.K. Woldarska, et al. 1997. Spectrum of clinico-pathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. *J. Am. Coll. Cardiol.* 30:1512–1520. doi:10.1016/S0735-1097(97)00332-X

Cregler, L.L. 1989. Progression from hypertrophic cardiomyopathy to dilated cardiomyopathy. *J. Natl. Med. Assoc.* 81:820–826.

D’Angelo, D.D., Y. Sakata, J.N. Lorenz, G.P. Boivin, R.A. Walsh, S.B. Laggett, and G.W. Dorn Jr. 1997. Transgenic Galphag overexpression induces cardiac contractile failure in mice. *Proc. Natl. Acad. Sci. USA.* 94:8121–8126. doi:10.1073/pnas.94.15.8121

Dávila-Román, V.G., G. Vedala, P. Herrero, L. de las Fuentes, J.G. Rogers, D.P. Kelly, and R.J. Gropler. 2002. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. *J. Am. Coll. Cardiol.* 40:271–277. doi:10.1016/S0735-1097(02)01967-8

Davis, J., H. Wen, T. Edwards, and J.M. Metzger. 2007. Thin filament inhibition by restrictive cardiomyopathy mutant R193H troponin I induces Ca2+-independent mechanical tone and acute myocyte remodeling. *Circ. Res.* 100:1494–1502. doi:10.1161/01.RES.0000262412.34364.50

de Jonge, H.W., D.H. Dekkers, B.C. Tilly, and J.M. Lamers. 2002. Cyclic stretch and endothelin-1 mediated activation of chloride channels in cultured neonatal rat ventricular myocytes. *Clin. Sci.* 103(Suppl 48):1485–1515.

Deinum, J., J.M. van Gool, M.J. Kofflard, F.J. ten Cats, and A.H. Danser. 2001. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. *Hypertension.* 38:1278–1281. doi:10.1161/ hany.1011.096114

Dobrin, J.S., and D. Lebeche. 2010. Diabetic cardiomyopathy: signaling defects and therapeutic approaches. *Expert Rev. Cardiovasc. Ther.* 8:373–391. doi:10.1586/erc.10.17

Dolci, A., R. Dominici, D. Cardinale, M.T. Sandri, and M. Panettiache. 2008. Biochemical markers for prediction of chemotheraphy-induced cardiototoxicity: systematic review of the literature and recommendations for use. *Am. J. Clin. Pathol.* 130:688–695. doi:10.1309/AICPB66LHRVMQDR

Edwards, B.S., R.S. Zimmerman, T.R. Schwab, D.M. Heublein, and J.C. Burnett Jr. 1988. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. *Circ. Res.* 62:191–195.

Esposito, G., S.V. Prasad, A. Rapacciuolo, L. Mao, W.J. Koch, and H.A. Rockman. 2001. Cardiac overexpression of a G grind marker blocks induction of extracellular signal-regulated kinase and c-Jun(NH2-terminal) kinase activity in vivo pressure overload. *Circulation.* 103:1435–1458.

Flavigny, J., M. Souchet, P. Sébilon, I. Berbrei-Bertrand, B. Hainque, A. Mallet, A. Bril, K. Schwartz, and L. Carrier. 1999. COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes. *J. Mol. Biol.* 294:443–456. doi:10.1006/jmbi.1999.2376

Force, T., R. Hajjar, F. Del Monte, A. Rzenzweig, and G. Chourouk. 1999. Signalizing pathways mediating the response to hypertrophic stress in the heart. *Gene Expr.* 7:337–348.

Freedom, R.M., S.J. Yoo, D. Perrin, G. Taylor, S. Petersen, and R.H. Anderson. 2005. The morphological spectrum of ventricular noncompaction. *Cardiol. Young* 15:345–364. doi:10.1017/S1047951105000752

Friend, N., and E.N. Olson. 2003. Cardiac hypertrophy: the good, the bad, and the ugly. *Annu. Rev. Physiol.* 65:45–79. doi:10.1146/annurev.physiol.65.090201.142243

Geng, Y.J., Y. Ishikawa, D.E. Vatner, T.E. Wagner, S.P. Bishop, S.F. Vatner, and C.J. Homcy. 1999. Apoptosis of cardiac myocytes in Gsalpha transgenic mice. *Circ. Res.* 84:34–42.

Gill, C., R. Mestril, and A. Samali. 2002. Losing heart: the role of apoptosis in heart disease—a novel therapeutic target? *FASEB J.* 16:135–146. doi:10.1096/fj.01-0628com
Miyata, S., W. Minobe, M.R. Bristow, and L.A. Leinwand. 2000. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ. Res. 86:386–390.

Mogensen, J., T. Kubo, M. Duque, W. Uribe, A. Shaw, R. Murphy, J.R. Gimeno, P. Elliott, and W.J. McKenna. 2003. Idiopathic restrictive cardiomyopathy: is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest. 111:209–216.

Molkentin, J.D., and G.W. Dorn II. 2001. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63:391–426. doi:10.1146/annurev.physiol.63.1.391

Molkentin, J.D., J.R. Lu, C.L. Antos, B. Markham, J. Richardson, J. Robbins, S.C. Grant, and N. Olson. 1998. A calcium-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:215–228. doi:10.1016/S0092-8674(00)81573-1

Nagata, K., R. Liao, F.R. Eberi, N. Satoh, B. Chevalier, C.S. Aspstein, and T.M. Suter. 1998. Early changes in excitation-contraction coupling: transition from compensated hypertrophy to failure in Dahl salt-sensitive rat myocytes. Cardiovasc. Res. 37:467–477. doi:10.1016/S0008-6363(97)00278-2

Narula, N., J. Haider, R. Virmani, T.G. DiSalvo, F.D. Kolodgie, R.J. Hajjar, U. Schepis, M.J. Semigran, G.W. Dec, and B.A. Kshaw. 1996. Apoptosis in myocytes in end-stage heart failure. N. Engl. J. Med. 335:1182–1189. doi:10.1056/NEJM1996101733515163

F. Schram, K., S. De Girolamo, S. Madani, D. Munoz, F. Thong, and G. Sweeney. 2010. Leptin regulates MMP-2, TIMP-1 and collagen synthesis via p38 MAPK in HL-1 murine cardiomyocytes. Cell. Mol. Biol. Lett. 15:551–565. doi:10.2478/s11658-010-0027-z

Schwarz, K., Y. Lecarpentier, J.L. Martin, A.M. Lompré, J.J. Mercadier, and B. Sweigart. 1981. Isometric diastolic dysfunction correlates with speed of myocardial contraction. J. Mol. Cell. Cardiol. 13:1071–1075. doi:10.1016/0022-2878(81)90279-2

Seidman, J.G., and C. Seidman. 2001. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 104:557–567. doi:10.1016/S0092-8674(00)00242-2

Senssian, C., M.J. Healey, D. Fatkin, M. Giewat, C. Duffy, C.E. Seidman, and J.G. Seidman. 2001. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 33:2055–2060. doi:10.1016/jjmcc.2001.1466

Shen, W.K., W.D. Edwards, S.C. Hammill, R.R. Bailey, D.J. Ballard, and B.J. Gersh. 1995. Sudden unexpected nontraumatic death in 54 young adults: a 30-year population-based study. Am. J. Cardiol. 76:148–152. doi:10.1006/ajca.1999.0047-2

Shoujioma, I., K. Sato, Y. Izuimaya, S. Schiefler, M. Ito, R. Liao, W.S. Colucci, and K. Walsh. 2005. Disruption of coordinated cardiac hypertrophy and angiogenesis contribute to the transition to heart failure. J. Clin. Invest. 115:2108–2118. doi:10.1122/JCI24682

Silberbach, M., T. Gorenc, R.E. Hershberger, P.I. Stork, P.S. Steyger, and C.T. Roberts Jr. 1999. Extracellular signal-regulated protein kinase activation is required for the anti-hypertrophic effect of atrial natriuretic factor in neonatal rat ventricular myocytes. J. Biol. Chem. 274:24858–24864. doi:10.1074/jbc.R101013200

Simpson, P., A. McGrath, and S. Savion. 1982. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ. Res. 51:787–801.

Smith, C.S., P.A. Bottomley, S.P. Schulman, G. Gerstenblith, and R.G. Weiss. 2006. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation. 114:1151–1158. doi:10.1161/CIRCULATIONAHA.106.613646

Tajen, T., L.J. De Wind, H.W. Lim, and J.D. Molkentin. 2000. Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc. Natl. Acad. Sci. USA. 97:1196–1201. doi:10.1073/pnas.97.3.1196

Teekakirikul, P., S. Eiminga, O. Taka, R. Alcalai, L. Wang, H. Wakimoto, M. Nayor, T. Konno, J. Gorham, C.M. Wolf, et al. 2010. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by nonmyocyte proliferation and requires Tgf-β. J. Clin. Invest. 120:3520–3529. doi:10.1172/JCI24028

Torre-Amonie, G., S. Kapadia, L.J. Bibb, D.R. Bies, J.B. Young, and D.L. Mann. 1996. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human myocardium. Circulation. 93:704–711. doi:10.1161/01.CIR.93.3.704

VanKirk, K.L., S.M. Factor, and L.A. Leinwand. 1996. Mice expressing mutant myosin heavy chains are a model for familial hypertrophic cardiomyopathy. Mol. Med. 2:556–567.

Wang, L., J.G. Seidman, and C.E. Seidman. 2010. Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann. Intern. Med. 152:513–520. W181.

Weiford, B.C., V.D. Subbarao, and K.M. Mulhern. 2004. Noncompaction of the left ventricular myocardium. Circulation. 110:2597–2600. doi:10.1161/01.CIR.0000132478.60067.D0

Yamaji, K., S. Fujimoto, Y. Ikeda, K. Masuda, S. Nakamura, Y. Saito, and C. Yutani. 2005. Apoptotic myocardial cell death in the setting of arhythmogenic right ventricular cardiomyopathy. Acta Cardiol. 60:465–470. doi:10.2143/AC.60.5.2004965

Yang, Z., N.E. Bowles, S.E. Scherer, M.D. Taylor, D.L. Kearney, S. Ge, V.V. Nadvoletsky, G. DeFreitas, B. Carabello, L.I. Brandon, et al. 2006. Desmosomal dysfunction due to mutations in desmoplakin causes arhythmogenic right ventricular dysplasia/cardio-myopathy. Circ. Res. 99:646–655. doi:10.1161/01.RES.0000241442.19382.e0

Yousef, Z.R., P.W. Foley, K. Khajdooji, S. Chali, H. Sandman, N.U. Mohammed, and F. Levy. 2009. Left ventricular non-compaction: clinical features and cardiovascular magnetic resonance imaging. BMC Cardiovasc. Disord. 9:37. doi:10.1186/1471-2261-9-37

Zhang, Y.H., J.B. Youm, H.K. Sung, S.H. Lee, S.Y. Ryu, W.K. Ho, and Y.E. Earn. 2000. Stretch-activated and background non-selective cation channels in rat atrial myocytes. J. Physiol. 523:607–619. doi:10.1111/j.1469-7793.2000.00607.x

Cellular mechanisms of cardiomyopathy” Harvey and Leinwand

365